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Objective: Osteoarthritis (OA) patients experience exaggerated pain during movements such as walking.
Anti-nerve growth factor (NGF) antibodies have recently shown analgesic effects in OA patients. We
examined the effect of a single dose of anti-NGF antibody on pain during motion, joint edema and lesion
in a rat model of OA to determine whether the analgesic effect demonstrated in clinical studies can be
translated to a preclinical model.
Methods: Sodium monoiodoacetate (MIA)-induced arthritic rats that develop a right-left gait imbalance
when walking as an index of pain during motion. This imbalance was assessed using a gait analysis
system called “CatWalk”. Edema size and lesion score in the relevant knee joint were also measured. The
effect of a single intravenous injection of an anti-NGF monoclonal antibody AS2886401-00 on these
parameters was assessed.
Results: AS2886401-00 administered at 0.3 or 1 mg/kg on Day 3 post-MIA injection resulted in a sta-
tistically signiﬁcant improvement in gait imbalance even on Day 35. When gait measurement was set on
Week 3 post-MIA administration, administration of the antibody at a timing close to the gait mea-
surement, i.e., 1 or 24 h prior to the measurement, was less effective. AS2886401-00 did not suppress
either edema or lesion.
Conclusions: A single dose of anti-NGF antibody exerts a long-lasting analgesic effect on pain during
motion in a rat model of OA. This ﬁnding could be associated with the analgesic efﬁcacies that anti-NGF
antibodies have exhibited in clinical studies. It appears unlikely that analgesia is secondary to inhibition
of joint edema and lesion.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
In osteoarthritis (OA) patients, pain present at rest and typically
worsened by bearing weight on or moving the affected joint is a
primary symptom1. Aggravation of pain during motion leads to
limitedmovement and reduced quality of life of patients. Given that
drugs exert different efﬁcacies on relieving pain depending on the
motion state of the affected joint, the mechanism of pain during
motion might differ from that at rest2e4. While opioids appearG. Ishikawa, Drug Discovery
uba, Ibaraki 305-8585, Japan.
ikawa), yukari.koya@astellas.
Tanaka), yukinori.nagakura@
ternational. Published by Elsevier Leffective, they are associated with serious adverse effects5,6. Thus,
improved therapies are required to address pain during motion in
OA patients.
Nerve growth factor (NGF), a small secretory protein, has
important roles in the growth, maintenance, and survival of target
neurons7. The physiological actions of NGF are mediated via the
high-afﬁnity tyrosine kinase receptor tropomyosin receptor kinase
A (TrkA) and low-afﬁnity NGF receptor p75. NGF is critically
important in nociceptive function in mammalian species such as
humans8. Mutation in the TrkA gene led to congenital insensitivity
to pain in humans9. Regarding the involvement of NGF in the
pathophysiology of OA, the expression of NGF is upregulated in
chondrocytes and synovial ﬁbroblasts of OA patients10,11. The
expression and release of NGF might be induced by not only in-
ﬂammatory mediators but also mechanical stimuli in chon-
drocytes12. Recently, clinical studies have demonstrated that anti-td. All rights reserved.
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pain not only at rest but also during motion (when walking) in OA
patients13e16.
Here, we examined the effect of a single dose of an anti-NGF
monoclonal antibody on pain during motion (gait imbalance),
inﬂammation and joint lesion in a rat OA model to determine
whether the analgesic effect demonstrated in the clinical stud-
ies13e16 can be translated to a preclinical model, monoiodoacetate
(MIA)-induced arthritis in rats. This model is widely used as a
preclinical model of OA as the administration of MIA into intra-
articular space of the knee induces joint degeneration and
chronic pain-associated symptoms in rats that mimic aspects of
end-stage OAwith severe pain17. This MIA-induced pain is sensitive
to therapy with NSAIDs in the early phase (i.e., during the ﬁrst week
following MIA administration), but becomes resistant in the late
phase (e.g., Week 3 post-MIA administration)18e20. Since the pain
resistant to NSAIDs is a serious therapeutic issue21, evaluation of
efﬁcacy is conducted mainly at Week 3 post-MIA administration in
the present study. Gait imbalance during walking is used as an
index of pain duringmotion22, as the analgesic effects of drugs with
various mechanisms, such as morphine and tramadol, were suc-
cessfully evaluated using MIA-induced arthritic rats in our recent
study20.
Method
Animals
Adult male Sprague Dawley rats (Charles River, Kanagawa,
Japan) weighing 150e185 g and aged 6 weeks at the time of MIA
administration, were used. Animals were housed in groups of ﬁve
in a polycarbonate cage with woodchip bedding and free access to
standard laboratory chow and water. The animal room was main-
tained at a temperature of 23 ± 2C and humidity of 55% ± 10%with
a 12-h light/dark cycle (lights on at 07:30 h). Animals were accli-
mated to the housing facility for at least 3 days before the start of
experiments. Vendor health reports indicated that the rats were
free of known viral, bacterial and parasitic pathogens. All animal
experiments were approved by the Institutional Animal Care and
Use Committee of Astellas Pharma Inc. (Tokyo, Japan), which is
accredited by the Association of Assessment and Accreditation of
Laboratory Animal Care (AAALAC).
Drugs
An anti-NGF human IgG1 AS2886401-00was stably expressed in
Chinese hamster ovary (CHO) cells as previously described23.
Glutamine synthetase vectors pEE12.4 and pEE6.4 (Lonza, Basel,
Switzerland) were used as expression vectors. Cells were cultured
in CD CHO medium (Invitrogen, Carlsbad, CA, USA), and antibody
was puriﬁed from culture supernatant. AS2886401-00 was dis-
solved in phosphate-buffered saline (PBS) and intravenously (i.v.)
injected at 1 mL/kg at indicated time points prior to testing.
Antibody binding assay
The wells of MaxiSorp™ surface clear plates (384-well; Thermo
Fisher Scientiﬁc Inc., Waltham, MA, USA) were ﬁrst coated with
10 ng of rat b-NGF (R&D Systems, Minneapolis, MN, USA) in PBS
overnight at 4C. The plates were washed three times with Tris-
buffered saline and Tween 20 (TBST; pH 7.4, 20 mM Tris, 150 mM
NaCl, 0.05% Tween 20) before each addition of subsequent reagents.
After the plates were blocked with 50 mL of 20% Blocking One so-
lution (Nacalai Tesque, Kyoto, Japan)/TBST in each well for 1 h at
room temperature, AS2886401-00 or isotype control IgG (20 mL;0.001e3 mg/mL, respectively) in 5% Blocking One/TBST was then
added to the wells and incubated for 1 h at room temperature.
Horse radish peroxidase (HRP)-conjugated goat anti-human kappa
antibody (20 mL; SouthernBiotech, Birmingham, AL, USA) (1:500) in
5% Blocking One/TBST was added to the wells and incubated for a
further 1 h at room temperature followed by addition of 3,30,5,50-
tetramethylbenzidine (TMB) substrate (40 mL; Dako, Glostrup,
Denmark) to the wells and incubation for 10 min at room tem-
perature. After the reaction was stopped with 1 M sulfuric acid
(Wako Pure Chemical Industries, Ltd, Osaka, Japan), absorbancewas
measured at 450 nm using a microplate reader.
Cell-based NGF function evaluation assay
HEK293 cells stably expressing human TrkA were generated by
transfection with pcDNA3.1-V5-His-topo expression vector (Life
Technologies Corporation, Carlsbad, CA USA) encoding appropriate
TrkA cDNA cloned from melanoma and fetal brain cells. FuGENE6
transfection regent (Roche Applied Science, Indianapolis, IN, USA)
was used for stable transfection and G418 (Nacalai Tesque) as a
selection agent. HEK293 (TrkA) cells were maintained in Dulbecco's
modiﬁed Eagle's medium (DMEM) (Life Technologies Corporation)
supplemented with 10% fetal bovine serum (FBS), penicillin
(100 units/mL), streptomycin (100 mg/mL), and 200 mg/mL G418 at
37C with 5% CO2.
HEK293 cells expressing human TrkA were seeded at 2  104
cells per well into black-walled, clear-base 96-well poly-D-lysine-
coated plates (BD Biosciences, San Jose, CA, USA) in 100 mL of above-
mentioned DMEM media. The plates were incubated for 1 day at
37Cwith 5% CO2. On the day of measurement, cells were incubated
for 1 h at 37C and 5% CO2 in Hank's Balanced Salt Solution (HBSS)
containing 20 mM HEPES pH 7.4, 0.1% BSA and 2.5 mM probenecid
(SigmaeAldrich Chemical Co., St. Louis, MO, USA) and the calcium
(Ca2þ) indicator 1.55 mM Fluo-4 AM (Dojindo Laboratories, Kuma-
moto, Japan) was added. Cells were washed twice in 200 mL of the
above-mentioned Hank's buffer and allowed to incubate in 150 mL
of the buffer prior to the assay. Plates were then placed into a
Fluorescence Imaging Plate Reader (FLIPR) TETRA (Molecular De-
vices Corporation Japan, Tokyo, Japan) to measure cell ﬂuorescence
activity. AS2886401-00 and isotype control IgG were incubated
with rat b-NGF (40 and 150 ng/mL) for 30 min and added to cells in
a volume of 50 mL via the FLIPR. After addition of antibody/b-NGF,
changes in ﬂuorescence were monitored, and maximum increases
in ﬂuorescence signals were noted.
The mean ﬂuorescence value of ligand alone was 100% while
that of buffer alone was 0%, and data were presented as a per-
centage of the control value in concentrationeinhibition curves for
antibodies. The concentrationeresponse curves for rat b-NGF and
concentrationeinhibition curves for antibodies were calculated
using nonlinear regression analysis with GraphPad Prism® version
5 (GraphPad Software, San Diego, CA, USA).
AS2886401-00 concentration in plasma
Plasma samples from normal rats intravenously administered
AS2886401-00 at 0.003, 0.03 or 0.3 mg/kg (n ¼ 3) were collected
from the tail vein at 15 min, 24 h, 3 days, and 14 days post-
AS2886401-00 administration. Detection of AS2886401-00 in rat
plasmawas conductedwith the ELISA-based assay described above.
HRP-conjugated anti-human IgG antibody (Dako, Glostrup,
Denmark) (1:5000) in 5% Blocking One/TBST was used instead of
HRP-conjugated goat anti-human-k antibody. As a reference for
quantiﬁcation, a standard curve was established by serial dilution
of AS2886401-00 (0.003e10 mg/mL) diluted in non-treated normal
rat plasma.
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Rats were anesthetized with 3e4% isoﬂurane (Mylan Inc., Can-
onsburg, PA, USA). The right knee was shaved and disinfected with
70% ethanol and sodium MIA (SigmaeAldrich) saline was injected
into the joint cavity at a dose of 1 mg in 50 mL via the patellar lig-
ament. An intra-articular dose of 1 mgMIA per rat was employed in
accordance with a previous study on the relationship between the
dose of MIA and the severity of cartilage lesion24 or pain20. The
sham group was injected with sterile isotonic saline without MIA.
Animals were returned to the animal room after recovery from
anesthesia.
Gait analysis
Gait of animals during walking was measured using the auto-
mated gait analysis apparatus (Noldus, Wageningen, The
Netherlands) as described in detail previously20. The “max contact
area” and the “swing speed” parameters were determined by
analyzing the footprints left by the animals. Differences in param-
eter values between the right and left hind limbs were obtained by
subtracting the values of the right side (MIA-injected side) from
those of the left.
Time-course of effect of AS2886401-00 on arthritic pain
Rats were randomized by weight into two groups to receive
either MIA-injection (n ¼ 48) or sham operation (n ¼ 10). Gait
measurement before drug treatment was conducted on Day 2 post-
MIA administration to obtain baseline (pre-drug treatment) gait
parameter values of each animal. MIA-injected rats were random-
ized by baseline gait parameter values and body weight into four
groups (n ¼ 12 per group) to receive AS2886401-00 (0.1, 0.3 or
1 mg/kg, i.v.) or vehicle using SAS software (SAS Institute Inc., Cary,
NC, USA). AS2886401-00 or vehicle was administered on Day 3
post-MIA administration. The sham group (n¼ 10) received vehicle
solution. Time-course measurement (repeated measurements in
the same animal) of the gait (i.e., efﬁcacy evaluation) was con-
ducted on Days 4, 6, 10, 14, 17, 21, 24, 31, and 35 post-MIA admin-
istration. One of animals treated with 0.3 mg/kg of the drug was
excluded from the study due to deteriorating health condition
which was unlikely to be associated with drug treatment.
Inﬂuence of timing of intervention on analgesic outcome
Rats were randomized by weight into two groups to receive
MIA-injection (n ¼ 40) or sham operation (n ¼ 10). Gait measure-
ment was conducted the day before AS2886401-00 administration
to obtain the baseline (pre-drug treatment) gait parameter values
of each animal. MIA-injected rats were randomized by baseline gait
parameter values and body weight into four groups (n ¼ 10 per
group) to receive AS2886401-00 (0.1, 0.3 or 1 mg/kg, i.v.) or vehicle
using SAS software. The sham group (n ¼ 10) received vehicle so-
lution. AS2886401-00 or vehicle was administered at 1 h, 24 h, 7 or
18 days prior to efﬁcacy evaluation. Gait measurement (i.e., efﬁcacy
evaluation) was conducted on Week 3 post-MIA administration.
Note that the efﬁcacy evaluation 18 days after intervention corre-
sponded to that conducted in the time-course experiment above on
Day 21 post-MIA administration.
Evaluation of knee edema size
On the ﬁnal day of time-course measurement of the gait, knee
edema size on Day 35 post-MIA administration (Day 32 post-
AS2886401-00) was assessed in randomly selected animals(n ¼ 7 for each AS2886401-00 dose, n ¼ 7 for vehicle and n ¼ 5 rats
for sham). Knee diameter was measured using calibrated digital
calipers (Mitutoyo Co. Kanagawa, Japan), and differences in the
diameter between the right and left knee were determined by
subtracting the values of the left side from those of the right (MIA-
injected side), as previously described25.
Scoring of knee lesion
Macroscopic observation of tibial heads was conducted in all of
the animals which were subjected to time-course measurement of
the gait. Animals were sacriﬁced by exposure to a slowly rising
concentration of carbon dioxide after the ﬁnal measurement of the
gait on Day 35 post-MIA administration (Day 32 post-AS2886401-
00). The right knee was removed and dissected, and the tibia was
ﬁxed in 10% formalin neutral-buffered solution (Wako Pure
Chemical, Osaka, Japan). The observation and scoring of knee lesion
were conducted in accordance with the method in a previous
report24. Brieﬂy, the degree of lesion on the surface of the tibial
head was scored on a scale of 0e4 in a blinded manner as follows:
0 ¼ normal appearance, 1 ¼ rough surface, 2 ¼ moderate lesion of
cartilage surface, 3 ¼ severe lesion of subchondral bone,
4 ¼ appearance of osteophyte formation with severe lesion of
subchondral bone.
Statistical analysis
Analyses were performed using GraphPad Prism® version 5.
Parametric data were presented as mean ± standard deviation
(S.D.). Statistically signiﬁcant differences in parametric mean values
were assessed using the two-tailed Student's t test or Dunnett's
multiple comparison test. In the time-course experiment, two-way
repeated measures of an analysis of variance (ANOVA) test was
applied to assess differences in the response of the gait imbalance
to different doses of AS2886401-00 over time (comparison of the
effect of AS2886401-00 vs vehicle was conducted by Dunnett's
multiple comparison test on Day 35 post-MIA administration).
Statistically signiﬁcant differences in non-parametric mean scores
were assessed via Wilcoxon rank sum test or KruskaleWallis test
with post-hoc Dunn's multiple comparison test. Differences were
considered statistically signiﬁcant when P values were less than
0.05. The percentage effect of drug in gait measurement experi-
ment was calculated using the following formula:
(Difference between right and left values in each rat mean
difference between right and left values in MIA-treated vehicle
group)  100/(mean difference in sham group mean difference
in MIA-treated vehicle group).
Results
Function of rat NGF and neutralization of AS2886401-00
We ﬁrst conﬁrmed the binding activity of AS2886401-00 using
an ELISA-based assay. Results showed that the binding signal
increased relative to AS2886401-00 concentration, conﬁrming
binding of AS2886401-00 to rat b-NGF (Fig. 1).
To evaluate the inhibitory activity of AS2886401-00 against rat
b-NGF, we constructed a rat b-NGF function evaluation system to
measure cytosolic Ca2þ levels, as b-NGF induces Ca2þ inﬂux in cells
expressing TrkA. In this system, cytosolic Ca2þ levels in cells
expressing human TrkA were increased by rat b-NGF in a dose-
dependent manner [Fig. 2(A)]. We then evaluated the effect of
AS2886401-00 on the cytosolic Ca2þ inﬂux in this system. Using rat
Fig. 1. Conﬁrmation of binding of AS2886401-00 to rat b-NGF. Binding activities of
AS2886401-00 and isotype control IgG to rat b-NGF detected using ELISA-based assay.
Data are presented as each replicate from duplicate experiments.
Fig. 3. In vivo pharmacokinetic proﬁle of AS2886401-00. AS2886401-00 was intra-
venously administered to rats, and plasma samples were drawn at indicated time
points. Plasma concentration of AS2886401-00 was measured using an ELISA-based
method. The points on each graph represent the mean ± S.D. for three rats.
G. Ishikawa et al. / Osteoarthritis and Cartilage 23 (2015) 925e932928b-NGF as a stimulator, we conﬁrmed that AS2886401-00 inhibited
the cytosolic Ca2þ inﬂux in a dose-dependent manner. AS2886401-
00 at a concentration of 0.1 and 1 mg/mL completely blocked the
effect of 40 and 150 ng/mL of rat b-NGF [Fig. 2(B)], respectively.Pharmacokinetic study of AS2886401-00
We then investigated the plasma concentration of AS2886401-
00 in normal rats. Plasma AS2886401-00 concentrations
increased dose dependently, and concentrations exceeding 0.1 mg/
mL were detected in rat plasma for more than 14 days following a
single intravenous administration of AS2886401-00 at 0.3 mg/kg
(Fig. 3). The lower detection limit of AS2886401-00 concentration
was below 0.01 mg/mL. AS2886401-00 was eliminated from the
plasma in rats injected with AS2886401-00 at 0.003 mg/kg within
15 min and at 0.03 mg/kg within 4 days.Fig. 2. Increasing cytosolic calcium inﬂux by rat b-NGF and inhibition by
AS2886401-00. Cytosolic calcium concentration increase in human TrkA expressed in
HEK293 cells by rat b-NGF detected using FLIPR (A). Cytosolic calcium inﬂux inhibition
by AS2886401-00, with 40 and 150 ng/mL rat b-NGF used as stimulator (B). Antibody
concentration range from 0.01 to 1 mg/mL. Data are presented as each replicate from
duplicate experiments.Time-course of effect of AS2886401-00 on arthritic pain
MIA treatment caused signiﬁcant gait imbalances between
ipsilateral and contralateral hind limbs for the max contact area
[Fig. 4(A), F [1, 20] ¼ 111, P < 0.0001 compared to the sham group,
two-way repeated measures of ANOVA] and the swing speed
[Fig. 4(B), F [1, 20] ¼ 160, P < 0.0001]. Treatment with AS2886401-
00 on Day 3 post-MIA administration resulted in a statistically
signiﬁcant improvement in gait imbalance regarding max contact
area (F [3, 43] ¼ 14.6, P < 0.0001, two-way repeated measures of
ANOVA) and swing speed (F [3, 43]¼ 19.7, P < 0.0001). The effect of
AS2886401-00 at 0.3 or 1 mg/kg i.v. was statistically signiﬁcant
compared to corresponding vehicle administration, even on Day 35
[Fig. 4(A) and (B), P < 0.0001, Dunnett's multiple comparison test].
Rats exhibited no abnormal behavioral changes at any of the tested
doses.Inﬂuence of timing of intervention with AS2886401-00 on analgesic
outcome
AS2886401-00 administered 1 h prior to gait measurement (i.e.,
efﬁcacy evaluation) did not improve either max contact area (F [3,
36] ¼ 0.953, P ¼ 0.43, one-way ANOVA) or swing speed (F [3,
36] ¼ 1.97, P ¼ 0.14) [Fig. 5(A) and (E)]. Treatment 24 h prior to
efﬁcacy evaluation also failed to improve max contact area (F [3,
36] ¼ 1.99, P ¼ 0.13) or swing speed (F [3, 36] ¼ 2.08, P ¼ 0.12)
[Fig. 5(B) and (F)]. In contrast, treatment 7 days prior to efﬁcacy
evaluation signiﬁcantly rectiﬁedmax contact areawith amaximum
effect of 54% ± 32% (F [3, 35] ¼ 4.12, P ¼ 0.013) and swing speed
with a maximum effect of 56% ± 14% (F [3, 36] ¼ 5.43, P ¼ 0.0035)
compared to corresponding vehicle control (Dunnett's multiple
comparison test) [Fig. 5(C) and (G)]. Treatment 18 days prior to
efﬁcacy evaluation also signiﬁcantly improved themax contact area
with a maximum effect of 82% ± 27% (F [3, 43] ¼ 16.6, P < 0.0001)
and swing speed with a maximum effect of 67% ± 13% (F [3,
43] ¼ 14.3, P < 0.0001), [Fig. 5(D) and (H)]. Note that the data ob-
tained on efﬁcacy evaluation 18 days after the intervention
[Fig. 5(D) and (H)] duplicated those obtained in efﬁcacy evaluation
on Day 21 post-MIA administration in the time-course experiment
[Fig. 4(A) and (B)].Effect of AS2886401-00 on knee edema size and lesion score
MIA treatment resulted in a statistically signiﬁcant increase in
knee diameter [Fig. 6(A), P ¼ 0.022, by Student's t test] and knee
lesion score compared to the corresponding sham control on Day
Fig. 4. Long-lasting effect of a single administration of AS2886401-00 on the
imbalance in max contact area (A) and swing speed (B) measured by gait analysis
paradigm in MIA-induced arthritis rats. Imbalances in max contact area and swing
speed immediately developed following MIA administration and were sustained
during the experimental period (open squares). AS2886401-00 was intravenously
administered on Day 3 post-MIA administration. Data represent the difference be-
tween ipsilateral and contralateral hind limb and are presented as mean ± S.D. (n ¼ 12
for 0.1 or 1 mg/kg of AS2886401-00, n ¼ 11 for 0.3 mg/kg of AS2886401-00, n ¼ 12 for
vehicle and n ¼ 10 for sham). Statistical comparison was performed on Day 35.
***P < 0.001 compared to corresponding vehicle (Dunnett's multiple comparison test).
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neWhitney test]. AS2886401-00 treatment on Day 3 post-MIA
administration resulted in a statistically signiﬁcant increase in
knee diameter measured on Day 35 post-MIA administration
compared to vehicle control (F [3, 24] ¼ 33.2, P < 0.0001, one-way
ANOVA, Fig. 6(A)). This treatment did not show a statistically sig-
niﬁcant effect on knee lesion score measured on Day 35 post-MIA
administration compared to vehicle control [KruskaleWallis test,
P ¼ 0.13; Fig. 6(B)].Discussion
In an MIA-induced mono-arthritic model of OA, rats developed
signiﬁcant right-left imbalances between hind limbs in the gait
parameters over amonth. A single administration of AS2886401-00
signiﬁcantly rectiﬁed these imbalances for a long period of time,
suggesting an analgesic effect on pain during motion. To our
knowledge, this is the ﬁrst report examining the analgesic effect of
anti-NGF antibody on pain during motion in a preclinical animal
model of OA. Although OA-like degenerative morphological change
is not established in early phase post-MIA administration26, pain-
related behavior is present even at this phase (up to 1 week post-MIA administration)26,27. Gait imbalance was actually present
even in the early phase of the present study. Notably, NGF is
elevated even in the early phase (e.g., Day 4 post-MIA administra-
tion)28, and such elevations in this phase might be involved in both
the maintenance and development of OA-associated pain.
AS2886401-00 treatment applied in the early phase (on Day 3 post-
MIA administration) might exert a long-lasting analgesic effect by
inhibiting these functions of NGF. This effect of AS2886401-00 in
the present study could be associated with the analgesic efﬁcacies
that anti-NGF antibodies have exhibited in recent clinical stud-
ies13e16 in patients with OA. It should, however, be noted that the
treatment on Day 3 post-MIA administration did not fully reﬂect
the clinical studies where anti-NGF antibodies were applied to
patients with established degenerative morphological change
rather than patients in early phase (i.e., without morphological
change).
The anti-NGF antibody AS2886401-00 bound to rat b-NGF and
potently inhibited the function of b-NGF by neutralization. These
in vitro activities suggest that 0.1 mg/mL of AS2886401-00
completely blocked 40 ng/mL of rat b-NGF function. Our phar-
macokinetic in vivo study demonstrated that plasma concentra-
tions of AS2886401-00 were maintained at levels exceeding
0.2 mg/mL for 14 days post-intravenous administration at 0.3 mg/
kg in rats. AS2886401-00 at 0.3 mg/kg might therefore exert
persistent inhibition of gait imbalance, which is presumably
mediated by endogenous NGF. However, more precise pharma-
cokinetic studies are warranted to further support the analgesic
effect of AS2886401-00. Namely, the measurement of plasma
concentration of AS2886401-00 for more than 14 days would help
determine the long-lasting effect of this drug (e.g., Day 35 post-
MIA administration) because the present study has the
mismatch between pharmacokinetic data and gait assessment
with regards to the time points. Further, the measurement of
plasma NGF concentration in MIA-induced arthritic rats might
help reveal the relationship between concentrations of antigen
(NGF) and antibody (AS2886401-00).
The study regarding the inﬂuence of the timing of intervention
with AS2886401-00 on analgesic outcomes suggested that inter-
vention at an early time point (e.g., 7 or 18 days prior to efﬁcacy
measurement) was more effective in the improvement of gait
imbalance than that at late time points (e.g., 1 or 24 h prior to ef-
ﬁcacy measurement). NGF has been suggested to bind to TrkA re-
ceptors expressed in the sensory neuronal terminal, where it is
subsequently transported to the dorsal root of ganglia (DRG) with
increased expression of nociception-associated receptors and
channels at the membrane surface, which sensitizes the neu-
rons29,30. In addition, TrkA expression is reportedly increased in the
ipsilateral DRG innervating the knee joint in MIA-induced arthritic
rats compared with non-osteoarthritic control rats31, suggesting
that upregulation of TrkA may amplify the NGF-TrkA pathway. The
effects of the anti-NGF antibody might be mediated via the inhi-
bition of either the expression of nociception-associated receptors
and channels or ampliﬁcation of the NGF-TrkA pathway. One
possible explanation for the more efﬁcient effect of AS2886401-00
in gait improvement when treated at early time points might be
that it takes long periods of time for anti-NGF antibody to sufﬁ-
ciently inhibit the upregulation of these nociception-related
molecules.
Based on the results of the present study, AS2886401-00 does
not appear to suppress knee edema and lesion. Administration of
AS2886401-00 resulted in a statistically signiﬁcant increase knee
edema size in MIA-induced arthritis in rats, a ﬁnding which is
consistent with previous reports32,33. Although the mechanism of
this effect remains to be elucidated, it might involve an increase in
weight distribution to arthritic joint due to pain reduction.
Fig. 5. Inﬂuence of timing of intervention with AS2886401-00 on analgesic outcome. Imbalance in max contact area (left) and swing speed (right) was measured by the gait
analysis paradigm in MIA-induced arthritis rats. AS2886401-00 was intravenously administered 1 h (A, E) (n ¼ 10 per group), 24 h (B, F) (n ¼ 10 per group), 7 days (C, G) (n ¼ 10 per
group) or 18 days (D, H) (n ¼ 12 for 0.1 or 1 mg/kg of AS2886401-00, n ¼ 11 for 0.3 mg/kg of AS2886401-00, n ¼ 12 for vehicle and n ¼ 10 for sham) prior to gait measurement (i.e.,
efﬁcacy evaluation) which was conducted at Week 3 post-MIA administration. Data represent the difference between ipsilateral and contralateral hind limb and are presented as
mean ± S.D. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to corresponding vehicle control (Dunnett's multiple comparison test). þþþP < 0.001 compared to corresponding sham
control (Student's t test).
G. Ishikawa et al. / Osteoarthritis and Cartilage 23 (2015) 925e932930AS2886401-00 did not show statistically signiﬁcant effect on knee
lesion score. This result may suggest that the anti-NGF antibody
does not affect joint degeneration, although this should be carefully
considered due to the following limitations. As the present study
was conducted with only macroscopic scoring of joint lesion, more
precise histopathological examination of joint tissues is necessary
to concludewhether the anti-NGFantibody has a diseasemodifying
effect or not. Another concern is that chemically (MIA)-induced
joint degenerationmight be too severe for the anti-NGF antibody to
exhibit an inhibitory effect. Nevertheless, based on the ﬁndings in
the present study, it seems unlikely that AS2886401-00 improvedgait imbalance (an index of pain) indirectly through inhibition of
knee joint edema and lesion. Given that clinically-used analgesic
drugs, such as morphine and tramadol, improved the gait imbal-
ance in MIA-induced arthritic rats in the previous study20, the
noted improvement in gait imbalance in response to AS2886401-
00 might be mainly due to its analgesic effect.
Consideration of the etiology and pathophysiology underlying
the arthritis might be important due to differences between
arthritis chemically-induced in rats and that in OA patients. As one
animal model might fail to completely replicate OA in humans, the
use of other categories of animal models of OA, such as surgically-
Fig. 6. Effect of AS2886401-00 on knee diameter (A) and knee lesion score (B) in
rats with MIA-induced arthritis. Knee diameter on Day 35 post-MIA administration
was assessed (n ¼ 7 for each AS2886401-00 dose, n ¼ 7 for vehicle and n ¼ 5 for sham).
The differences in the diameter between the right and left knee were determined by
subtracting the values of the left side from those of right (MIA-injected side). Data are
presented as mean ± S.D. ***P < 0.001 compared to vehicle-treated MIA rats (Dunnett's
multiple comparison test). þP < 0.05 compared to sham control rats (Student's t test)
(A). The ipsilateral tibias were removed on Day 35 post-MIA administration. The score
of each tibia was deﬁned as the mean scores of two independent observers. Each circle
indicates the score in each individual. The bar represents the median of scores in each
group (n ¼ 12 for 0.1 or 1 mg/kg of AS2886401-00 dose, n ¼ 11 for 0.3 mg/kg of
AS2886401-00, n ¼ 12 for vehicle and n ¼ 10 for sham). þþþP < 0.001 compared to
sham control rats (Wilcoxon rank sum test) (B).
G. Ishikawa et al. / Osteoarthritis and Cartilage 23 (2015) 925e932 931induced models and animals developing spontaneously occurring
OA should be considered in future studies. Another aspect to be
investigated in the future is the use of multilateral behavioral
endpoints of pain. Although gait imbalance has recently been used
as a pain index, further precise assessments of its validity are
necessary. Measurement of behavioral endpoints in addition to gait
imbalance, such as stimulus-evoked hind paw withdrawal, should
also be considered in future.
In conclusion, a single dose of anti-NGF antibody exerted a long-
lasting analgesic effect on pain during motion in a rat model of OA.
This ﬁnding could be associated with the analgesic efﬁcacies that
anti-NGF antibodies have exhibited in recent clinical studies in
patients with OA. Intervention at early time points was more
effective in inducing analgesia than that at late time points. This
analgesic effect does not appear to be secondary to suppression of
knee joint edema and lesion.Contributions
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